
               gene mutations in sporadic breast cancer patients from Brazil by unknown
a SpringerOpen Journal
Mangone et al. SpringerPlus  (2015) 4:23 
DOI 10.1186/s40064-015-0787-zRESEARCH Open AccessATM gene mutations in sporadic breast cancer
patients from Brazil
Flavia Rotea Mangone1, Elisabete C Miracca1, Harriet E Feilotter2, Lois M Mulligan3 and Maria Aparecida Nagai1,4*Abstract
Purpose: The Ataxia-telangiectasia mutated (ATM) gene encodes a multifunctional kinase, which is linked to important
cellular functions. Women heterozygous for ATM mutations have an estimated relative risk of developing breast cancer
of 3.8. However, the pattern of ATM mutations and their role in breast cancer etiology has been controversial and
remains unclear. In the present study, we investigated the frequency and spectrum of ATM mutations in a series of
sporadic breast cancers and controls from the Brazilian population.
Methods: Using PCR-Single Strand Conformation Polymorphism (SSCP) analysis and direct DNA sequencing, we
screened a panel of 100 consecutive, unselected sporadic breast tumors and 100 matched controls for all 62 coding
exons and flanking introns of the ATM gene.
Results: Several polymorphisms were detected in 12 of the 62 coding exons of the ATM gene. These polymorphisms
were observed in both breast cancer patients and the control population. In addition, evidence of potential ATM
mutations was observed in 7 of the 100 breast cancer cases analyzed. These potential mutations included six missense
variants found in exon 13 (p.L546V), exon 14 (p.P604S), exon 20 (p.T935R), exon 42 (p.G2023R), exon 49 (p.L2307F), and
exon 50 (p.L2332P) and one nonsense mutation in exon 39 (p.R1882X), which was predicted to generate a truncated
protein.
Conclusions: Our results corroborate the hypothesis that sporadic breast tumors may occur in carriers of low
penetrance ATM mutant alleles and these mutations confer different levels of breast cancer risk.
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The Ataxia-telangiectasia mutated (ATM) gene encodes a
multifunctional kinase, which is linked to important cellu-
lar functions (Derheimer and Kastan 2010; Shiloh and Ziv
2013). Individuals carrying two ATM alleles with loss-of-
function mutations are affected with Ataxia-Telangiectasia
(A-T), which is an autosomal recessive syndrome charac-
terized by progressive cerebellar ataxia, oculocutaneous
telangiectasia, immunodeficiency, hypersensitivity to ion-
izing radiation, and cancer susceptibility (Gatti et al. 1991;
Savitsky et al. 1995a; Ambrose and Gatti 2013). The esti-
mated incidence of A-T is 1:40,000 to 1:100,000 live births* Correspondence: nagai@usp.br
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in any medium, provided the original work is p(Easton, 1994). Patients with A-T have an increased risk of
developing cancer compared with non-A-T individuals
(Taylor and Byrd 2005; Mavrou et al. 2008). The frequency
of individuals heterozygous for a mutation in ATM is esti-
mated to be 0.5 - 1% in the general population (Swift et al.
1986; Easton 1994). Individuals heterozygous for A-T mu-
tations, who are phenotypically normal, may exhibit in-
creased radio- and chemo-sensitivity and an increased
relative risk of carcinogenesis (Swift et al. 1991; West et al.
1995). An increased relative risk of breast cancer was
identified for female A-T heterozygotes; while, the propor-
tion of sporadic breast cancers in the general population
that is due to ATM mutations remains controversial (Swift
et al. 1987; Ahmed and Rahman 2006; Mavrou et al.
2008). Somatically occurring ATM mutations are also pre-
valent in a number of sporadic human cancers, most not-
ably leukemias and carcinomas of the breast and lung
(Cremona and Behrens, 2014).is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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spanning approximately 150 kb of genomic DNA (Savitsky
et al. 1995a; Savitsky et al. 1995b). ATM is structurally
complex, containing 66 exons, and encodes a protein of
3056 amino acids (~350 kDa) that is related to the phos-
phatidylinositol 3-kinase (PI3-kinase) superfamily (Savitsky
et al. 1995a, Lavin et al. 1995). The COOH-terminal region
of the ATM protein shows similarity to several check-
point/damage response proteins from other organisms, in-
cluding TOR1 and TOR2, TEL1p, ATR, RAD3p, MEC1pC,
MEI-41, and DNA-PK (Mavrou et al. 2008; Bensimon et al.
2011). ATM-knockout mice show A-T-like phenotypes,
including neurological abnormalities, immunodeficiency,
chromosomal instability, radiosensitivity, and the develop-
ment of lymphomas (Xu et al. 1996; Barlow et al. 1996;
Liao and Van Dyke. 1999; Deng and Brodie 2001; Shiloh
and Ziv 2012). ATM belongs to the class of caretaker
tumor suppressor genes that defend genome integrity
(Levitt and Hickson 2002). Irradiated A-T cells had defects
in the activation of the G1/S, S phase, and G2 checkpoints
(Beamish and Lavin 1994; Derheimer and Kastan 2010).
ATM is believed to be involved in multiple cellular pro-
cesses that occur in response to DNA damage, including
cell cycle check point control, DNA repair, and apoptosis
(Derheimer and Kastan 2010; Shiloh and Ziv 2013). ATM
is one of the main sensors for DNA damage evoked by
genotoxic agents, such as ionizing radiation (Rotman and
Shiloh 1999; Thompson and Schild 2002; Liang et al.
2009). Members of the PI3-kinase superfamily of serine/
threonine protein kinases, such as ATM and DNA-
dependent protein kinase (DNA-PK) have been implicated
in cell cycle checkpoint control in response to DNA dam-
age (Derheimer and Kastan 2010; Sperka et al. 2012).
ATM is considered an important transducer of DNA dam-
age signaling via phosphorylation of downstream effectors,
which results in a kinase cascade that works to promote
genetic stability (Canman and Lim 1998; Khanna et al.
1998; Khosravi et al. 1999; Cortez et al. 1999; Li et al.
2000; Maya et al. 2001).
The size and complexity of the ATM gene make the
search for mutations and identification of genotype-
phenotype associations difficult, especially for the mis-
sense mutations primarily identified in heterozygous sub-
jects. The nature and distribution of the ATM mutations
found in A-T patients are variable with no specific hot
spot (Yuille and Coignet 1998; Sandoval et al. 1999;
Mavrou et al. 2008). More than 80% of A-T patients have
ATM-truncating mutations; however, exon-skipping and
missense mutations are also observed (Renwick et al.
2006; Mavrou et al. 2008). Detected mutations are believed
to cause structural or functional effects on the final protein,
abolishing ATM function. On the other hand, the majority
of ATM variants described so far in sporadic leukemia and
breast cancers are missense base substitutions (Prokopcovaet al. 2007; Broeks et al. 2008), making it difficult to distin-
guish missense mutations that affect protein function from
sequence polymorphisms with no effect on normal ATM
protein activity.
While the spectrum of ATM mutations in classical A-T
patients is well established, the pattern of ATM mutations
and their role in breast cancer etiology remains unclear
(Broeks et al. 2008; Milne 2009). The aim of the present
study was to investigate the frequency and the spectrum
of ATM mutations in a series of sporadic breast cancer
and control samples from the Brazilian population.
Results
DNA samples from a series of 100 breast cancer patients
(tumor and normal tissues) and 100 control individuals
were screened for ATM gene mutations. Sixty-four sets of
primers were used to amplify all coding exons and flank-
ing intron sequences of the ATM gene (Vorechovsky et al.
1996). The amplified DNA fragments were screened by
PCR-Single Strand Conformation Polymorphism (SSCP)
analysis and the samples showing band mobility shifts
were further analyzed by direct DNA sequencing. This
analysis led to the identification of 24 distinct sequence
variants (Tables 1 and 2). The polymorphism p.P1054R
(Table 1), which has been implicated in breast cancer and
linked to F858L (Larson et al. 1997–1998; Fletcher et al.,
2010), could not be detected by SSCP screening. The pres-
ence of this polymorphism in our population could be
confirmed only by re-sequencing some of the breast can-
cer cases and controls showing the polymorphism p.
F858L (Additional file 1); therefore, the SSCP technique
had low sensitivity for this mutation. The majority of vari-
ants observed were base substitutions within the ATM
coding region. One base substitution, one deletion, and
two insertions were observed in the introns of the ATM
gene.
Seventeen of the ATM variants were detected in DNA
samples from both breast cancer patients and the con-
trol population and were, thus, classified as polymor-
phisms. The polymorphisms observed in patients and
controls are summarized in Table 1. Among these, five
of the base substitutions were synonymous changes that
did not affect amino acid sequences and 8 were non-
synonymous changes (Table 1).
Seven unique DNA sequence variants were observed ex-
clusively in samples from breast cancer patients and were
classified as potential ATM mutations (Table 2). The alter-
ations observed were distributed throughout the ATM
coding sequence with no specific clustering, which would
have suggested no mutational hot spot. The spectrum of
the ATM variants observed only in breast tumors con-
sisted of six missense mutations affecting exons 13, 14, 20,
42, 49, and 50 and one nonsense mutation affecting exon
39. Three of the base substitutions resulted in conservative










7 c.378 T > A p.D126E Non-Synonymous Neutral
7 c.1287-18delT N/A Non-coding -
9 c.735C > T p.V245V Synonymous Neutral
13 c.1744 T > C p.F582L Non-Synonymous Neutral
15 c.2119 T > C p.S707P Non-Synonymous Neutral
16 c.2193C > T p.Y731Y Synonymous Neutral
18 c.2442C > A p.D814E Non-Synonymous Neutral
19 c.2572 T > C p.F858L Non-Synonymous Damaging
20 c.2685A > G p.L895L Synonymous Neutral
20 c.2805G > C p.T935T Synonymous Neutral
23 c.3118A > G p.M1040V Non-Synonymous Neutral
24 c.3161C > G p.P1054R Non-Synonymous Damaging
32 c.4578C > T p.P1526P Synonymous Neutral
39 c.5557G > A p.D1853N Non-Synonymous Neutral
55 c.8536 + 13insT N/A Non-coding -
56 c.8653 + 30insT N/A Non-coding -
62 c.9372 + 8A > C N/A Non-coding -
http://genetics.bwh.harvard.edu/pph2/; http://provean.jcvi.org/genome_submit_2.php;
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M231; and p.L2307F, cases 72TL and M214) and three led
to non-conservative changes (p.T935R, case M214; p.
G2023R, case M294; and p.L2332P, cases 112TL and
M214). Analyses of DNA from Case M115 identified a non-
sense mutation in exon 39 (p.R1882X), which was notTable 2 Potential mutations in the ATM gene identified in Bra
Exon position Nucleotide change Residue Functional im
13 c.1636C > G p.L546V Damaging
14 c.1810C > T p.P604S Damaging
20 c.2804C > G p.T935R Neutral
39 c.5647C > T p.R1882X Protein trunca
42 c.6067G > A p.G2023R Damaging
49 c.6919C > T p.L2307F Damaging
50 c.6995 T > C p.L2332P Neutral




**LOH, indicates loss of the wild type allele.
***age at diagnosis.previously reported in sporadic breast cancer patients and
was predicted to lead to protein truncation (Table 2). Two
breast tumors demonstrated two distinct ATM variants that
were classified as potential causal missense mutations, but
several breast tumors and controls displayed multiple ATM
variants classified as polymorphisms. The SIFT and Poly-
Phen algorithms were used to evaluate the potential func-
tional effect of the missense variants, which could be
classified as damaging (potential disease-causing mutation)
or neutral variants (Tables 1 and 2). Two of the 13 (15.4%)
variants identified in both control and breast cancer pa-
tients and 4 of the 6 (67%) potential missense mutations
identified only in breast cancer patients were classified as
damaging.
DNA samples from the primary breast cancer patients
were also examined for the occurrence of loss of hetero-
zygosity (LOH) for markers D11S897, D11S1818, and
D11S2000 that span approximately 10 cM of the chromo-
somal region 11q22-23 where the ATM gene is located.
Allelic loss was detected in 36/90 (40%) tumors that were
informative (heterozygous) for at least one of the markers
examined. The frequency of allelic loss at each of the
markers analyzed is listed in Table 3. Case M115 had the
nonsense mutation in exon 39 (p.R1882X) as well as LOH
for marker D11S1818 (Figure 1), suggesting that ATM
function was abolished in this tumor. Three of the tumors
with potential ATM mutations also showed LOH for the
microsatellite markers on chromosomal region 11q23
(Table 2). However, the microsatellite markers used were
not located within the ATM gene. We sequenced all DNA
samples from normal and tumor tissues that had potential
ATM mutations (Table 2). Sequencing results showed evi-
dence of wild type allele loss in cases M214 and M231
harboring potential mutations (Figure 2) and in case
M115 with a nonsense mutation. In addition, two patients
showed two missense variants, classified as potential ATMzilian breast cancer patients
pact* LOH Sample Age*** (years) Clinical stage
No M227 46 I
Yes** M231 50 IV
Yes** M214 51 III
tion Yes** M115 75 III
No M294 45 II
No 72TL 67 II
Yes M214 51





Table 3 Summary of Loss of Heterozygosity (LOH) on
chromosome 11q in primary breast tumors
Locus No. of cases analyzed Allelic loss/informative
cases (%)*
D11S897 100 17/71 (24)
D11S1818 100 26/69 (38)
D11S2000 100 22/84 (26)
*Informative cases: individuals heterozygous for the microsatellite
marker examined.
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deleterious based on the prediction of functional impact
(M214, p.L2307F; M227, p.L546V) and one variant pre-
dicted to be neutral (M214, p.T935R; M227, p.L2332P).
We also identified three tumors harboring ATM variants
classified as polymorphisms, such as p.S707P, p.F858L,
and p.M1040V, with evidence of wild type allele loss.
Discussion
Epidemiological studies have suggested that A-T hetero-
zygous individuals are at increased relative risk for can-
cer, especially breast cancer (Thompson et al. 2005;
Ahmed and Rahman 2006). Hence, several studies have
investigated the frequency, relative risk, and clinical sig-
nificance of ATM mutations in breast cancer patients
(Ahmed and Rahman 2006; Tavtigian et al. 2009; Graña
et al. 2011). In the present study, we examined DNA
from a series of 100 breast cancer patients without a
family history of breast cancer and 100 healthy individ-
uals for ATM gene mutations. To the best of our know-
ledge, this is the first study to investigate the occurrence
of ATM mutations in a Brazilian breast cancer popula-
tion. We were able to identify variants occurring only in
the breast cancer population. Overall, 7% of the patient
population had ATM gene alterations classified as poten-
tial mutations, with the majority being missense variants.
Low penetrance, potentially deleterious ATM missense
variants, which were associated with an increased risk
for breast cancer, have been found in other breast cancer
populations (Scott et al. 2002; Thorstenson et al. 2003;
Graña et al. 2011). Using SIFT and PolyPhen tools to
predict the possible impact of the amino acid changes
on the ATM function, we found 4 of the 6 variants iden-
tified only in breast cancer patients could be classified as
potentially deleterious mutations that might impair
ATM function, suggesting a causality to the disease. Fur-
ther experimental and clinical studies are needed to bet-
ter understand the association of these variants with
breast cancer risk. In addition, we also identified a spor-
adic breast cancer patient carrying a nonsense mutation,
with loss of the wild-type allele, which could be a
biologically significant ATM mutation. Although this
variant, p.R1882X, has been described in Brazilian A-T
patients (Mitui et al., 2003; Coutinho et al. 2004); todate, it has not been described in sporadic breast cancer
patients.
To our knowledge the exact prevalence of A-T heterozy-
gotes in the Brazilian population is unknown. However,
there was a high prevalence for nonsense, splicing site, or
frameshift ATM mutations in 27 Brazilian families with
classical A-T, and these led to truncated proteins (Coutinho
et al. 2004). We identified one individual carrying a non-
sense mutation that was predicted to generate a truncated
protein, a phenomenon frequently observed in classical A-
T (Sandoval et al. 1999; Demuth et al. 2011). This finding is
consistent with the frequency of 0.2 – 1% of A-T carriers in
the general population, as predicted from epidemiological
studies (Easton, 1994). The breast cancer patient carrying a
nonsense mutation was constitutively heterozygous for the
mutation, but a DNA sample from her tumor showed LOH
for the wild-type allele, which is consistent with the tumor
suppressor role predicted for the ATM gene in the patho-
genesis of breast cancer. We identified two patients with
two missense variants classified as potential ATM muta-
tions. Each patient harbored one variant classified as dele-
terious (M214, pL2307F; M227, pL546V) and another
variant classified as neutral (M214, p.T935R; M227,
pL2332P). In addition, we identified some tumors with
ATM variants classified as polymorphisms with evidence of
LOH of the wild type allele, suggesting there was selection
of the polymorphic allele during the tumorigenic process.
Loss of the wild-type allele of the ATM gene has also been
reported in tumors of individuals with familial breast cancer
(Bay et al. 1999) and early-onset breast cancer (Izatt et al.
1999). Reduced levels of ATM mRNA and protein have also
been reported in sporadic breast tumors, implicating ATM
gene inactivation in the development and progression of
breast cancer (Ding et al. 2004; Bhattacharya et al. 2013;
Bueno et al. 2014). There has been a high frequency of
DNA methylation observed in advanced breast tumors and
attributed to reduced ATM expression and function (Vo
et al. 2004). Furthermore, recent studies demonstrated
that over-expression of microRNAs, such as miR181 and
miR421, may be involved in ATM down-regulation in
breast cancer (Fang et al. 2010; Bueno et al. 2014).
More than 70% of the ATM mutations described in
classical A-T families are frameshift or nonsense muta-
tions leading to protein truncation (Cavaciutti et al.
2005; Goldgar et al. 2011). To date, most of the ATM
mutations observed in breast cancer patients, including
the data reported here, are missense mutations distrib-
uted throughout the ATM gene, but mainly outside of
the PI-3 K domain or other putative functional domains
defined by sequence similarity (Savitsky et al. 1995a;
Bosotti et al. 2000; Thorstenson et al. 2001; Tavtigian
et al. 2009). Thus, it is difficult to define clear genotype-
phenotype associations, and the clinical implications of
these mutations remain unknown.
Figure 1 ATM nonsense mutation in a sporadic breast cancer patient. A, SSCP analysis of exon 39 (case M115); B, sequence profile for exon
39 showing a nonsense mutation R1882X; C, loss of heterozygosity at marker D11S1818; N, normal DNA; T, tumor DNA.
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mutation-carriers are more radiosensitive than lympho-
cytes from normal donors (West et al. 1995), suggesting
that even low radiation dosages might be deleterious for
such individuals, increasing their risk for breast cancer or
inducing severe complications. Many clinical studies have
tested the hypothesis that ATM heterozygote breast cancer
patients exhibit enhanced radiosensitivity; yet, most of
those studies failed to show a clear association between
ATM mutation status and increased radiosensitivity
(Ramsay et al. 1996; Appleby et al. 1997; Ramsay et al.
1998; Weissberg et al. 1998; Shayeghi et al. 1998). Iannuzzi
et al. (2002) reported that breast cancer patients harboring
ATM missense mutations are more susceptible to develop
subcutaneous late responses after radiation therapy. Using
an ATM kinase assay, Scott et al. (2002) demonstrated
that only 1 of 5 missense mutations detected in breast
cancer patients abrogated ATM kinase activity when
expressed in AT1ABR cells. The ATM protein is a large
serine-threonine protein kinase that plays a key role in the
cellular response induced by ionizing radiation by directly
interacting and phosphorylating key components of differ-
ent DNA damage response pathways such as TP53,
MDM2, and BRCA1. Therefore, we cannot rule out the
potential effect of these missense mutations on interindi-
vidual ionizing radiation sensitivity and cancer risk (Banin
et al. 1998; Kastan and Lim 2000; Wang et al. 2000).Recently, Byrd et al. (2012) reported on a breast cancer pa-
tient with a severe reaction to radiotherapy who was a car-
rier of biallelic ATM mutations, including a missense
mutation c.8672C >A (p.Gly2891Asp), and displayed re-
sidual ATM kinase activity. The expression of a missense
mutated ATM protein, especially resulting from a non-
conservative missense mutation, may alter the ATM pro-
tein stability and function (Gatti et al. 1999). In addition,
low levels of ATM protein expression have been associ-
ated with severe adverse normal tissue reaction in breast
cancer patients, suggesting that ATM protein levels may
represent an independent predictive biomarker for clinical
radiosensitivity (Fang et al. 2010).
The limitations of the present study are the small
number of samples and low sensitivity of the method-
ology; although, we identified several ATM polymor-
phisms in both breast cancer patients and the control
population. In an effort to better understand the etiology
and to identify factors associated with the predisposition
to breast cancer, several groups have recently used next-
generation sequencing (NGS) to determine the pattern
of mutations associated with the disease. Despite the
large number of studies using NGS, no investigation has
specifically focused on the ATM gene. Studies using ex-
ome sequencing technologies in breast cancer showed a
high prevalence of mutations and variants in genes such
as BRCA1, BRCA2, TP53, and PIK3CA, but few reported
Figure 2 Representative examples of the sequencing analysis of potential ATM mutations in sporadic breast cancer patients. A, upper
panel: reference sequence; B, middle panel: sequencing electropherograms from normal tissue samples from breast cancer patients (227 N,
231 N, 214 N, and 72NL); C, lower panel: sequencing electropherograms from tumor tissue samples from breast cancer patients (227 T, 231 T,
214 T, and 72TL). Case 227 showed two potential ATM missense mutations without evidence of LOH; Cases 214 and 231 showed potential ATM
mutations with evidence of loss of the wild type allele.
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2012). A study evaluating 691 sporadic breast tumors,
identified mutations affecting genes such as PIK3CA,
FGFR2, TP53, and ERBB2, but no alterations in the ATM
gene (Wilkerson et al. 2014). On the other hand, studies
evaluating hereditary breast cancer have identified muta-
tions and variants of ATM in a subset of cases (Snape
et al. 2012; Kurian, et al. 2014). Thus, at present, data re-
lated to the ATM gene in sporadic breast tumors are
limited; thus, it is difficult to make an adequate assess-
ment of its role in sporadic breast cancer. Our group re-
cently analyzed exome sequencing data from breast
cancer samples, including one of the cases (M294) in-
cluded here, and our preliminary (unpublished) results
identified a larger number of ATM alterations compared
with the data obtained from SSCP screening and direct
DNA sequencing. Using SSCP analysis, we identified
two missense variants in case M294 (p.L895L and p.
G2023R); however, using exome sequencing, we found
five missense variants (p.Y731Y, pP872S, pL895L, p.
N1983S, and p.G2023R) and many INDELs and basesubstitutions in the introns of the ATM gene in this
same case (Additional file 2). Thus, the NGS technique
is a promising approach to better estimate the number
of ATM variants related to breast cancer.
Conclusions
Our results support the hypothesis that ATM heterozy-
gotes carrying low penetrance ATM mutant alleles are at
risk for breast cancer. There is a potential increased sen-
sitivity of these heterozygotes to ionizing radiation;
therefore, identifying these carriers may have an impact
on the treatment offered to these individuals. We have
identified several ATM variants in this study that may
potentially act as disease-causing missense mutations.
However, further functional studies to evaluate the bio-
logical effects of the potential ATM missense mutations
observed in breast cancer patients and large case–con-
trol studies using NGS (amplicon and/or exome sequen-
cing) are needed. These investigations should contribute
to the understanding of the role played by the ATM gene
in the etiology and pathobiology of breast cancer.
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Samples
Paired normal and tumor DNA samples were obtained
from 100 sporadic breast cancer patients with no family
history of A-T at Hospital do Cancer A.C. Camargo, São
Paulo, Brazil (from 1993 to 1998). The age of the patients
at the time of operation ranged from 25 to 78 years (me-
dian 48 years). Tumor samples were dissected to remove
residual normal tissue before freezing and stored in liquid
nitrogen. The largest diameter of the tumors was re-
corded. The number of lymph node metastases was deter-
mined by microscopic examination of an average of 24
lymph nodes per patient. Tumor metastasis to the lymph
nodes was detected in 58 patients. All cases were sub-
mitted for histopathological review of tumor sections to
confirm the diagnosis. All tumors were classified as inva-
sive ductal carcinomas according to the World Health
Organization Histological Typing of Breast Tumors classifi-
cation, and the clinical disease stage of each patient was de-
termined according to the 5th Edition of the UICC TNM
classification of malignant tumors. In addition, DNA
was extracted from one hundred control blood samples
from healthy and unrelated women at Hemocentro-
Hospital das Clínicas da Faculdade de Medicina da
Universidade de São Paulo. The Institutional Ethics
Committee approved this study and all subjects studied
(patients and matched controls) signed an informed
consent for participation.
DNA extraction
Normal and tumoral tissue was ground to a powder
using a frozen tissue pulverizer (Termovac). The powder
was resuspended in 1 mL of lysis buffer (10 mM Tris–
HCl, pH 7.6, 1 mM EDTA, and 0.6% SDS) with 100 μg/
mL proteinase K, and incubated at 37°C overnight. High
molecular weight DNA was extracted with phenol-
chloroform and precipitated with ethanol. Blood samples
were collected in EDTA (5 mL) and DNA was extracted
as described by Lahiri & Nurnberger (1991) and adapted
by Salazar et al. (1998).
Loss of heterozygosity (LOH) analysis
The LOH analysis for the chromosomal region 11q23
was performed using three polymorphic microsatellite
markers (D11S897, D11S1818, and D11S2000). Primer
sequences for these markers were obtained from the
Genome Data Base (http://www.ncbi.nlm.nih.gov/probe/).
Allelic loss assays were performed as previously described
(Miracca et al. 1999). Allelic loss, determined by densito-
metric scan (UltroScan XL; Pharmacia), was considered to
be complete or partial if the intensity of one allele was re-
duced by at least 40% in the tumor compared with normal
DNA samples from the same patient. LOH was scored for
informative (heterozygous) patients only.Mutation analysis
Mutation analyses were performed by Single Strand
Conformation Polymorphism (PCR-SSCP) and direct
DNA sequencing analysis, as previously described (Miracca
et al. 1999). Briefly, sixty-four sets of primers were used
to amplify exons 2 to 63 of the ATM gene, as previously
described by Vorechovsky et al. (1996). Radiolabeled
PCR reactions were performed in 25 μL volumes using
50–100 ng of genomic DNA template, containing
0.1 mCi of [α32P-dCTP] (Amersham, specific activity,
3000 Ci mmol−1). Amplification products were diluted
ten-fold in a buffer containing 95% formamide, 20 mM
EDTA, 0.05% bromophenol blue, and 0.05% xylene cya-
nol, heated at 83°C for 5 min, and applied (3 μL per
lane) on two 6% polyacrylamide non-denaturing gels,
one containing 5% glycerol and the other 10% glycerol.
Electrophoresis was performed at 6 W for 14–16 h at
room temperature with two cooling fans. Band shift
mobility was detected by autoradiography of dried gels
using Kodak X-Omat XAR film with an intensifying
screen for 12–48 h at −70°C. DNA samples with evi-
dence of sequence variants in the SSCP analysis were
characterized by direct sequencing using the Big Dye
Terminator kit (Life Technologies™) according to the man-
ufacturer’s specifications. Sequencing reaction products
were purified by ethanol/EDTA precipitation and re-
suspended in Hi-Di™ formamide (Life Technologies™).
Samples were separated by electrophoresis on the ABI
Prism 3730 DNA Analyzer (Life Technologies™) and the
results were evaluated in Mutation SurveyorR DNA Vari-
ant Analysis Software version 3.30 (Softgenetics LLC). The
variants identified were evaluated using the following
public ATM databases to determine if changes were novel
or already known: http://chromium.liacs.nl/LOVD2/home.
php?select_db=ATM; NCBI dbSNP - http://www.ncbi.nlm.
nih.gov/projects/SNP/snp_ref.cgi?geneId=472; Ensembl -
http://www.ensembl.org/Homo_sapiens/Info/Index; and
EVS - http://evs.gs.washington.edu/EVS/. In addition,
the algorithms PolyPhen-2 (http://genetics.bwh.harvard.
edu/pph2/) and SIFT (http://provean.jcvi.org/genome_
submit_2.php) were used to predict the possible impact
of amino acid changes on the function of the ATM
protein.Additional files
Additional file 1: Representative example of the sequencing analysis of
a breast cancer patient harboring both variants p.F858L and p.P1054R.
Additional file 2: Summary of the ATM variants observed by exome
sequencing analysis in Tumor and Normal tissue of one breast
cancer patient (M294) Chromosomal coordinates of the ATM
variants observed by exome sequencing analysis of Tumor and
Normal tissues from one breast cancer patient (M294). The results were
analyzed using the Golden Helix GenomeBrowser (www.goldenhelix.
com/GenomeBrowse/).
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